Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibroma (PN): Primary analysis of KOMET (NCT04924608), a phase 3, international, randomized, placebo-controlled study


Por: Chen, AP, Coyne, GHO, Wolters, P, Martin, S, Farschtschi, S, Blanco, I, Chen, ZP, Darrigo, LG Jr, Eoli, M, Whittle, JR, Nishida, Y, Lamarca, R, de la Rosa, R, Adeyemi, A, Herrero, I, Llorente, N, Diede, SJ, Dombi, E and Wolkenstein, P

Publicada: 1 jun 2025
Resumen:


Filiaciones:
NCI, Div Canc Treatment & Diag, Dev Therapeut Clin, NIH, Bethesda, MD USA
NCI, Dev Therapeut Clin, Bethesda, MD USA
NCI, Ctr Canc Res, Pediat Oncol Branch, Bethesda, MD USA
Univ Med Ctr Hamburg Eppendorf, Dept Neurol, Hamburg, Germany
Hosp Germans Trias I Pujol, Clin Genet Dept, Barcelona, Spain
Sun Yat Sen Univ, Canc Ctr, Dept Neurosurg Neurooncol, State Key Lab Oncol South China, Guangzhou, Peoples R China
Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Sao Paulo, Brazil
Fdn IRCCS Inst Neurol Carlo Besta, Dept Expt Neurooncol, Milan, Italy
Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Australia
Nagoya Univ Hosp, Dept Rehabil, Nagoya, Japan
Alexion, AstraZeneca Rare Dis, Barcelona, Spain
Alexion, AstraZeneca Rare Dis, Boston, MA USA
Merck & Co Inc, Rahway, NJ USA
Univ Paris Est Creteil UPEC, Univ Paris Est Creteil, Henri Mondor Hosp,Assistance Publ Hop Paris, AP HP,Dept Dermatol,Natl Referral Ctr Neurofibroma, Paris, France
ISSN: 0732183X





JOURNAL OF CLINICAL ONCOLOGY
Editorial
American Society of Clinical Oncology, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA, Estados Unidos America
Tipo de documento: Meeting Abstract
Volumen: 43 Número: 16_SUPPL
Páginas:
WOS Id: 001690387200010
imagen Bronze

MÉTRICAS